Publication Name	World Journal of Gastroenterology
Manuscript ID	116020
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Basic Study
Article Title	Growth arrest specific 6 ameliorated inflammation and portal pressure through activating efferocytosis in cholestasis and portal hypertension
Manuscript Source	Invited Manuscript
All Author List	Gu-Qing Luo, Jin-Bo Zhao, Zheng-Hao Wu, Jia-Yun Lin, Chi-Hao Zhang, Guang-Bo Wu, Qiang Fan, Xiao-Liang Qi, Hong-Jie Li, Meng Luo and Lei Zheng
Funding Agency and Grant Number	Funding Agency Grant Number Postdoctoral Scientific Research Foundation of Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine 202401023 Shanghai Municipal Commission of Health and Family Planning 20244Y0195 Shanghai Municipal Commission of Health and Family Planning 20234Y0132 National Natural Science Foundation of China 82100639 National Natural Science Foundation of China 82200630 National Natural Science Foundation of China 81970526
Corresponding Author	Lei Zheng, MD, PhD, Department of General Surgery, Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai Jiao Tong University, No. 639 Zhizaoju Road, Huangpu District, Shanghai 200011, China. zl1055174020@163.com
Key Words	Portal hypertension; Cholestatic liver disease; Growth arrest specific 6; Efferocytosis; MER proto-oncogene; Tyrosine kinase
Core Tip	The current study revealed that defective efferocytosis was related to portal hypertension (PHT) in mice model of cholestasis. Administration of recombinant growth arrest specific 6 (Gas6) ameliorated elevated intrahepatic vascular resistance and portal pressure in cholestasis. Gas6 enhanced macrophage efferocytosis by activating MerTK, which relieved inflammation and eventually alleviated liver sinusoidal endothelial cell dysfunction and PHT.
Citation	Luo GQ, Zhao JB, Wu ZH, Lin JY, Zhang CH, Wu GB, Fan Q, Qi XL, Li HJ, Luo M, Zheng L. Growth arrest specific 6 ameliorated inflammation and portal pressure through activating efferocytosis in cholestasis and portal hypertension. World J Gastroenterol 2026; In press

Received	2025-10-31 06:30
Peer-Review Started	2025-10-31 06:30
First Decision by Editorial Office Director	2025-12-18 09:40
Return for Revision	2025-12-18 09:40
Revised	2025-12-31 14:35
Publication Fee Transferred
Second Decision by Editor	2026-02-28 02:32
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2026-02-28 03:10
Articles in Press	2026-02-28 03:10
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com